AMGN logo Amgen +
Amgen
+

Amgen (AMGN) Business News

Track Amgen in real time with a live news feed covering Amgen stock news, official press releases, company announcements, and an archive of historical Amgen news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

PRNewsWire

9:00 AM | Tuesday | Sep 22, 2026

news photo
Loading...

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity  Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease  THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.

Read full article redirect
9:00 AM | Tuesday | Sep 22, 2026

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

PRNewsWire

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity  Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease  THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Sep 14, 2026

FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®

PRNewsWire

Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting.

Read full article arrow
News Thumbnail
4:01 PM | Wednesday | Sep 9, 2026

AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

PRNewsWire

THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Sep 8, 2026

IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

PRNewsWire

Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints  THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone.

Read full article arrow
News Thumbnail
4:01 PM | Wednesday | Sep 2, 2026

AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE

PRNewsWire

THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.

Read full article arrow
News Thumbnail
3:18 AM | Monday | Aug 31, 2026

AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE

PRNewsWire

Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Global Real-World Analyses Show Persistent Gaps in Lipid Management, With Many High-Risk Patients Undertreated and Not Achieving Recommended LDL-C Goals THOUSAND OAKS, Calif., Aug. 31, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments.

Read full article arrow
News Thumbnail
2:00 AM | Thursday | Aug 27, 2026

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

PRNewsWire

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif., Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE).

Read full article arrow
News Thumbnail